KEERTHIGA RAVEENDRAN: Open Payments
NPI 1205350741 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$913 in 47 payments from 11 companies in 2025. Trend: 2023 $668 · 2024 $504 · 2025 $913
Food & beverage: $913
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 11 | $176 |
| Janssen Pharmaceuticals, Inc | 8 | $159 |
| Teva Pharmaceuticals USA, Inc. | 5 | $99 |
| Alkermes, Inc. | 5 | $95 |
| Axsome Therapeutics, Inc. | 4 | $92 |
| Otsuka America Pharmaceutical, Inc. | 4 | $87 |
| E.R. Squibb & Sons, L.L.C. | 4 | $78 |
| Luye Pharma (USA) Ltd. | 3 | $76 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Corium, LLC | 1 | $17 |
Products named: INGREZZA, INVEGA SUSTENNA, AUSTEDO XR, ARISTADA, Auvelity, COBENFY, ERZOFRI EXTENDED-RELEASE, ABILIFY ASIMTUFII.
Industry payments across LA — which companies pay providers there.
